Literature DB >> 8101382

Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats.

P Hyytiä1.   

Abstract

The present study examined the role of mu- and delta-opioid receptors in alcohol drinking using antagonists selective for these receptor types. Food- and water-sated male and female AA (Alko, alcohol) rats consistently drank 10% alcohol during daily 30-min access periods in their home cages in the middle of the 12-h light phase. On 3 consecutive days, the animals received the mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP, 1 micrograms ICv), the delta-receptor antagonist N,N-diallyl-Try-Aib-Aib-Phe-Leu-OH (ICI 174,864, 3 micrograms ICV), or saline 15 min before the alcohol access period. Relative to saline, the mu-antagonist CTOP decreased alcohol drinking both by males and females progressively over the 3 treatment days, with a continued suppression on the first days after the termination of the administration. Treatment with the delta-antagonist ICI 174,864 had no effect on alcohol drinking in males, and produced transient hind limb dysfunction and barrel rolling in over half of the females. These results suggest that selective blockage of mu-opioid receptors is sufficient to suppress alcohol drinking in AA rats.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101382     DOI: 10.1016/0091-3057(93)90527-z

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  28 in total

1.  The Central Reinforcing Properties of Ethanol Are Mediated by Endogenous Opioid Systems: Effects of Mu and Kappa Opioid Antagonists.

Authors:  Michael E Nizhnikov; Elena I Varlinskaya; Norman E Spear
Journal:  Rev Argent Cienc Comport       Date:  2009

Review 2.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 3.  The opioidergic-alcohol link : implications for treatment.

Authors:  Vania Modesto-Lowe; Eleanor M Fritz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Recent Advances in the Neurobiology of Altered Motivation Following Bariatric Surgery.

Authors:  Julianna N Brutman; Sunil Sirohi; Jon F Davis
Journal:  Curr Psychiatry Rep       Date:  2019-11-09       Impact factor: 5.285

Review 5.  Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism.

Authors:  C Gianoulakis
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

6.  Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats.

Authors:  Angela Henderson-Redmond; Cristine Czachowski
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

7.  Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.

Authors:  Brendan M Walker; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-05-02       Impact factor: 7.853

Review 8.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

9.  The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake.

Authors:  Richard M van Rijn; Jennifer L Whistler
Journal:  Biol Psychiatry       Date:  2009-07-03       Impact factor: 13.382

10.  The role of endogenous beta-endorphin and enkephalins in ethanol reward.

Authors:  Andy Tseng; Khanh Nguyen; Abdul Hamid; Mayank Garg; Paul Marquez; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2013-06-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.